LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Revvity Inc

Închisă

SectorSănătate

84.98 -1.42

Rezumat

Modificarea prețului

24h

Curent

Minim

84.91

Maxim

86.01

Indicatori cheie

By Trading Economics

Venit

14M

55M

Vânzări

56M

720M

P/E

Medie Sector

37.513

35.733

EPS

1.18

Randament dividend

0.32

Marjă de profit

7.667

Angajați

11,000

EBITDA

22M

194M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+30.66% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.32%

3.13%

Următoarele câștiguri

3 nov. 2025

Data viitoare de dividende

7 nov. 2025

Următoarea dată ex-dividende

17 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-678M

10B

Deschiderea anterioară

86.4

Închiderea anterioară

84.98

Sentimentul știrilor

By Acuity

46%

54%

143 / 371 Clasament în Healthcare

Revvity Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 sept. 2025, 23:37 UTC

Acțiuni populare

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 sept. 2025, 20:41 UTC

Câștiguri

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 sept. 2025, 20:30 UTC

Câștiguri

GameStop 2Q Sales, Profit Rise

9 sept. 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 sept. 2025, 21:35 UTC

Câștiguri

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept. 2025, 21:32 UTC

Câștiguri

Oracle's Backlog Swells With Big Customer Deals -- Update

9 sept. 2025, 21:02 UTC

Achiziții, Fuziuni, Preluări

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 sept. 2025, 20:33 UTC

Câștiguri

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 sept. 2025, 20:26 UTC

Câștiguri

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept. 2025, 20:23 UTC

Câștiguri

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept. 2025, 20:12 UTC

Câștiguri

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 sept. 2025, 20:10 UTC

Câștiguri

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 sept. 2025, 20:10 UTC

Câștiguri

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 sept. 2025, 20:09 UTC

Câștiguri

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 sept. 2025, 20:09 UTC

Câștiguri

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 sept. 2025, 20:08 UTC

Câștiguri

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 sept. 2025, 20:08 UTC

Câștiguri

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 sept. 2025, 20:08 UTC

Câștiguri

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 sept. 2025, 20:08 UTC

Câștiguri

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 sept. 2025, 20:07 UTC

Câștiguri

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 sept. 2025, 20:06 UTC

Câștiguri

Oracle 1Q Software Revenue $5.72B >ORCL

9 sept. 2025, 20:06 UTC

Câștiguri

Synopsys 3Q Adj EPS $3.39 >SNPS

9 sept. 2025, 20:06 UTC

Câștiguri

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 sept. 2025, 20:05 UTC

Câștiguri

Oracle 1Q Rev $14.93B >ORCL

9 sept. 2025, 20:05 UTC

Câștiguri

Oracle 1Q EPS $1.01 >ORCL

9 sept. 2025, 20:05 UTC

Câștiguri

Synopsys 3Q EPS $1.50 >SNPS

9 sept. 2025, 20:05 UTC

Câștiguri

Oracle 1Q Services Revenue $1.35B >ORCL

9 sept. 2025, 20:05 UTC

Câștiguri

Oracle 1Q Adj EPS $1.47 >ORCL

9 sept. 2025, 20:05 UTC

Câștiguri

Oracle 1Q Hardware Revenue $670M >ORCL

Comparație

Modificare preț

Revvity Inc Așteptări

Obiectiv de preț

By TipRanks

30.66% sus

Prognoză pe 12 luni

Medie 112.73 USD  30.66%

Maxim 129 USD

Minim 100 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRevvity Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

7

Cumpărare

4

Păstrare

0

Vânzare

Sentiment

By Acuity

143 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat